OPKO Health

OPK Small Cap

Healthcare · Diagnostics & Research

Updated: Apr 5, 2026, 17:43 UTC

$1.14

+0.88% today

52W: $1.10 – $1.60

52W Low: $1.10 Position: 8% 52W High: $1.60

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

1.44x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$875.2M

Market Capitalization

Revenue Growth

-19.2%

YoY Revenue Growth

Profit Margin

-37.19%

Net profit margin

ROE

-17.14%

Return on Equity

Beta

1.49

Market sensitivity

Short Interest

7.6%

% of float sold short

Avg. Volume

2,763,545

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

6 analysts

Avg. Price Target

$3.40

+198.25% upside

Target Range

$1.40 – $8.50

About the Company

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose a

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 2,275 Exchange: NMS